Develop and manufacture oral, controlled-release pharmaceutical products. Produce generic pharmaceuticals under Abbreviated New Drug Applications (ANDA). Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 47% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $29.8B would still be left in the vault — a solid cushion for hard times.
The market pays 6.2× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 66% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 30% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 47% a year on average.
There is $29.8B in the vault; even if every debt were paid off, $29.8B would remain.
The stock sits at $0.26. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.